Mathias Jensen

Pre-clinical pathway to enzymatic generation of universal blood

Applicant

Mathias Jensen

Project drescription

Blood transfusions are recognised as an essential medicine bu the World Health Organisation (WHO), with almost 120 million transfusions performed worldwide each year. Despite this, the global blood supply remains imbalanced, with 40% of donations collected in high-income countries representing less than 16 % of the global population.  The universally compatible group O blood is under constant presure, even in high income countries, due to rising demands and an ageing donor population.

AB2O Biotech is developing an enzymatic technology to convert group A and B donor blood into the universal type O by a short, minimally invasive treatment that removes the immunogenic A and B antigens. By repurposing A and B units as universally compatible, we aim to address global shortages, reduce A and B blood wastage, and improve transfusion safety for patients worldwide.

Institution

Technical University of Denmark